Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 120 of the 124 references it cites were found in a registry or an index.

Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions

Open access

Abstract

Alzheimer’s disease (AD), once considered a rare disease, is now the most common form of dementia in the elderly population. Current drugs (cholinesterase inhibitors and glutamate antagonists) are safe but of limited benefit to most patients, offering symptomatic relief without successful cure of the disease. Since the last several decades, there has been a great need for the development of a treatment that might cure the underlying causes of AD and thereby slow its progression in vulnerable individuals. That is why phase I, II, and III studies that act on several fronts, such as cognitive improvement, symptom reduction, and enhancing the basic biology of AD, are imperative to stop the disease. This review discusses current treatment strategies, summarizing the clinical features and pharmacological properties, along with molecular docking analyses of the existing medications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells12010131

Cites

120 of 120 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The main drugs and their chemical structure approved in the treatment of Alzheimer’s disease.
Figure 1 The main drugs and their chemical structure approved in the treatment of Alzheimer’s disease.CC BY · PubMed Central
Figure 2 2D and 3D representation of the ligand–protein complex; (a) donepezil–AChE (A chain) complex; (b) donepezil–AChE (B chain) complex; (c) 3D structure of donepezil–AChE (chain A) complex; (d) 3D of donepezil–AChE (chain B) complex. Legend: GLY—glycine; TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine. The letters A and B represent the chain; the number represents the numbering of the amino acid.
Figure 2 2D and 3D representation of the ligand–protein complex; (a) donepezil–AChE (A chain) complex; (b) donepezil–AChE (B chain) complex; (c) 3D structure of donepezil–AChE (chain A) complex; (d) 3D of donepezil–AChE (chain B) complex. Legend: GLY—glycine; TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine. The letters A and B represent the chain; the number represents the numbering of the amino acid.CC BY · PubMed Central
Figure 3 2D and 3D diagrams representing the links between ligand and protein; (a) rivastigmine–AChE (chain A) complex; (b) rivastigmine–AChE (chain B) complex; (c) 3D structure of the donepezil—AChE (chain A) complex A; (d) 3D structure of the donepezil–AChE (chain B) complex. Legend: TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine; SER—serine; ARG—arginine; GLU—glutamic acid. The letters A and B represent the chains; the number represents the numbering of the amino acid.
Figure 3 2D and 3D diagrams representing the links between ligand and protein; (a) rivastigmine–AChE (chain A) complex; (b) rivastigmine–AChE (chain B) complex; (c) 3D structure of the donepezil—AChE (chain A) complex A; (d) 3D structure of the donepezil–AChE (chain B) complex. Legend: TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine; SER—serine; ARG—arginine; GLU—glutamic acid. The letters A and B represent the chains; the number represents the numbering of the amino acid.CC BY · PubMed Central
Figure 4 2D and 3D representation of the ligand–protein complex; (a) galantamine–AChE (chain A) complex; (b) galantamine–AChE (chain B) complex; (c) 3D structure of the galantamine–AChE (chain A) complex; (d) 3D structure of the galantamine–AChE (chain B) complex. Legend: TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine. The letters A and B represent the chain, and the number represents the numbering of the amino acid.
Figure 4 2D and 3D representation of the ligand–protein complex; (a) galantamine–AChE (chain A) complex; (b) galantamine–AChE (chain B) complex; (c) 3D structure of the galantamine–AChE (chain A) complex; (d) 3D structure of the galantamine–AChE (chain B) complex. Legend: TYR—tyrosine; TRP—tryptophan; PHE—phenylalanine; LEU—leucine. The letters A and B represent the chain, and the number represents the numbering of the amino acid.CC BY · PubMed Central
Figure 5 2D and 3D diagrams representing the link between memantine and NMDA; (a) 2D representation of the memantine- NMDA complex; (b) 3D representation of the Memantine—NMDA complex. Legend: ILE—isoleucine; MET—methionine; the letters C and D represent the chain, and the number represents the numbering of the amino acid.
Figure 5 2D and 3D diagrams representing the link between memantine and NMDA; (a) 2D representation of the memantine- NMDA complex; (b) 3D representation of the Memantine—NMDA complex. Legend: ILE—isoleucine; MET—methionine; the letters C and D represent the chain, and the number represents the numbering of the amino acid.CC BY · PubMed Central
Figure 6 Cleavage of APP. In the normal conditions, APP is cleaved by α-secretase. In abnormal conditions, APP will be cleaved by β-secretase, resulting in the accumulation and aggregations of small peptides called β-amyloid (Aβ), with the formation of amyloid plaques.
Figure 6 Cleavage of APP. In the normal conditions, APP is cleaved by α-secretase. In abnormal conditions, APP will be cleaved by β-secretase, resulting in the accumulation and aggregations of small peptides called β-amyloid (Aβ), with the formation of amyloid plaques.CC BY · PubMed Central
Figure 7 Main findings and directions of this research.
Figure 7 Main findings and directions of this research.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 124 references

Research works printed but not linked: 3

  1. Wolfe, M.S. (2018). The Molecular and Cellular Basis of Neurodegenerative Diseases: Underlying Mechanisms, Academic Press.
  2. BIOVIA, 2017, BIOVIA Discovery Studio Visualizer, Softw. Version, 20, 779
  3. Darvesh, 1998, Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation, J. Comp. Neurol., 393, 374, 10.1002/(SICI)1096-9861(19980413)393:3<374::AID-CNE8>3.0.CO;2-Z · DOI · Paper page

Cited by

See all 96

Metadata

Authors
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M.
Affiliations
  • University of Oradea (RO)
  • University of Petroleum and Energy Studies (IN)
  • Shanghai Jiao Tong University (CN)
  • Doctoral School of Biomedical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, 410087 Oradea, Romania
Corresponding author
  • Negru, Paul Andrei
  • Bungau, Simona Gabriela
Venue
Cells
Publisher
MDPI AG
Published
2022-12-28
Volume
12
Issue
1
Pages
131
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4313361457
Cited by
96
References
124
Citations by year
2026: 25 · 2025: 26 · 2024: 28 · 2023: 17
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Romanian Ministry of Research, Innovation and Digitisation (29 PFE/30.12.2021)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, pharmacotherapy, cholinesterase inhibitors, glutamate receptor antagonists, disease-modifying therapy, dementia, molecular docking, drug development, cognitive impairment
MeSH terms
Aged, Alzheimer Disease, Cholinesterase Inhibitors, Humans, Molecular Docking Simulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. https://app.cochat.ai/papers/10.3390/cells12010131
The paper
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022). Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions. Cells. https://doi.org/10.3390/cells12010131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.